Cartesian Therapeutics, Inc.
RNACNasdaq
$8.26
↓ -0.8%Jul 17 close · end-of-day
Price
1Y↓ -37.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$221.8M
Enterprise Value
$103.2M
P/E
—
P/S
125.0
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-34.9%
Dividend Yield
—
Revenue (TTM)
$1.8M
Net Income (TTM)
-$151.8M
Free Cash Flow (TTM)
-$77.4M
Gross Margin
—
Operating Margin
-8338.9%
Net Margin
-8550.6%
ROE
102.5%
ROIC
—
Debt / Equity
—
Net Cash
$118.6M
Return 1Y
-34.1%
Company profile
Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases.
- CEO
- Carsten Brunn
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 64
- Headquarters
- Maryland
Management & directors
- Brunn CarstenPresident and CEO
- Davis BlaineChief Financial Officer
- Miljkovic MilosChief Medical Officer
- English EmilyChief Operations Officer
- Seymour June AnnChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
RNAC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$78,000.00↓ -92.9%
Diluted EPS-$1.46↑ +114.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $16.6M | $85.1M | $110.8M | $26.0M | $38.9M | $2.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$56.8M | -$4.6M | $14.5M | -$86.4M | -$43.9M | -$143.4M |
| Net income | -$68.9M | -$25.7M | $35.4M | -$219.7M | -$77.4M | -$130.3M |
| Diluted EPS | -$0.68 | -$0.22 | $0.10 | -$49.76 | -$4.49 | -$5.02 |
| Operating cash flow | $34.9M | -$60.4M | -$31.6M | -$51.2M | -$23.7M | -$73.9M |
| Free cash flow | $34.1M | -$61.5M | -$32.8M | -$51.4M | -$32.8M | -$79.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -342.4% | -5.4% | 13.1% | -332.3% | -112.8% | -5127.1% |
| Net margin | -415.0% | -30.2% | 31.9% | -844.9% | -199.0% | -4658.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.4M | $387,000.00 | -$759,000.00 | $1.1M | $298,000.00 | $452,000.00 | $947,000.00 | $78,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $13.8M | -$17.6M | -$26.7M | -$21.9M | -$21.8M | -$21.1M | -$78.6M | -$26.5M |
| Net income | $13.8M | -$24.2M | -$10.3M | -$17.7M | $15.9M | -$35.9M | -$92.6M | -$39.2M |
| Diluted EPS | $0.54 | -$1.13 | $6.60 | -$0.68 | $0.50 | -$1.38 | -$3.46 | -$1.46 |
| Operating cash flow | -$14.4M | $13.7M | -$7.0M | -$23.1M | -$17.5M | -$15.6M | -$17.7M | -$22.1M |
| Free cash flow | -$16.0M | $7.5M | -$7.7M | -$24.2M | -$20.1M | -$16.9M | -$18.2M | -$22.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 41.1% | -4541.3% | 3521.9% | -1989.9% | -7319.1% | -4660.6% | -8304.0% | -33973.1% |
| Net margin | 41.4% | -6248.8% | 1350.9% | -1610.0% | 5330.9% | -7942.9% | -9775.7% | -50233.3% |
Company news
Jul 2, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-02 | Kalayoglu Murat | Option exercise | 758,001 | — | — | filing |
| 2026-04-02 | Hoge Elizabeth | Option exercise | 758,001 | — | — | filing |
| 2026-03-13 | Singer Michael | Gift | 6,555 | $0.00 | $0.00 | filing |
| 2026-01-06 | Brunn Carsten· President and CEO | Sale | 23,766 | $6.82 | $162,076.99 | filing |
| 2026-01-06 | Davis Blaine· Chief Financial Officer | Sale | 10,591 | $6.82 | $72,227.44 | filing |
| 2026-01-06 | Miljkovic Milos· Chief Medical Officer | Sale | 3,573 | $6.82 | $24,366.79 | filing |
| 2026-01-02 | Davis Blaine· Chief Financial Officer | Award | 37,000 | $0.00 | $0.00 | filing |
| 2026-01-02 | BARABE TIMOTHY C | Award | 2,600 | $0.00 | $0.00 | filing |
| 2026-01-02 | English Emily· Chief Operations Officer | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-01-02 | Singer Michael | Award | 2,600 | $0.00 | $0.00 | filing |
| 2026-01-02 | SPRINGER TIMOTHY A | Award | 2,600 | $0.00 | $0.00 | filing |
| 2026-01-02 | Kalayoglu Murat | Award | 2,600 | $0.00 | $0.00 | filing |
| 2026-01-02 | Seymour June Ann· Chief Accounting Officer | Award | 6,500 | $0.00 | $0.00 | filing |
| 2026-01-02 | DeSilva Nishan M | Award | 2,600 | $0.00 | $0.00 | filing |
| 2026-01-02 | Brunn Carsten· President and CEO | Award | 143,200 | $0.00 | $0.00 | filing |
| 2026-01-02 | Malik Kemal | Award | 2,600 | $0.00 | $0.00 | filing |
| 2026-01-02 | Miljkovic Milos· Chief Medical Officer | Award | 27,000 | $0.00 | $0.00 | filing |
| 2026-01-02 | ZENNER PATRICK J | Award | 2,600 | $0.00 | $0.00 | filing |
| 2025-12-30 | English Emily· Chief Operations Officer | Option exercise | 7,500 | $3.30 | $24,750.00 | filing |
| 2025-12-16 | Bot Adrian Ion | Award | 5,800 | $0.00 | $0.00 | filing |
| 2025-12-04 | BARABE TIMOTHY C | Buy | 30,000 | $6.86 | $205,797.00 | filing |
| 2025-11-28 | English Emily· Chief Operations Officer | Option exercise | 7,500 | $3.30 | $24,750.00 | filing |
| 2025-11-18 | Singer Michael | Gift | 20,000 | $0.00 | $0.00 | filing |
Latest 23 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.